Design of a New ?-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for ?-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation.

ABSTRACT: Some point mutations in ?-glucocerebrosidase cause either improper folding or instability of this protein, resulting in Gaucher disease. Pharmacological chaperones bind to the mutant enzyme and stabilize this enzyme; thus, pharmacological chaperone therapy was proposed as a potential treatment for Gaucher disease. The binding affinities of ?-1-C-alkyl 1,4-dideoxy-1,4-imino-d-arabinitol (DAB) derivatives, which act as pharmacological chaperones for ?-glucocerebrosidase, abruptly increased upon elongation of their alkyl chain. In this study, the primary causes of such an increase in binding affinity were analyzed using protein?ligand docking and molecular dynamics simulations. We found that the activity cliff between ?-1-C-heptyl-DAB and ?-1-C-octyl-DAB was due to the shape and size of the hydrophobic binding site accommodating the alkyl chains, and that the interaction with this hydrophobic site controlled the binding affinity of the ligands well. Furthermore, based on the aromatic/hydrophobic properties of the binding site, a 7-(tetralin-2-yl)-heptyl-DAB compound was designed and synthesized. This compound had significantly enhanced activity. The design strategy in consideration of aromatic interactions in the hydrophobic pocket was useful for generating effective pharmacological chaperones for the treatment of Gaucher disease.

SUBMITTER: Nakagome I 

PROVIDER: S-EPMC6222826 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature